It is a prescription-only medicine in the US and carries significant cardiovascular and dependence risks, making it unsuitable for unsupervised use
GLP-1 Patent Expiry: The Next Big Pharma Race Has Already Begun GLP-1 agonists like semaglutide, tirzepatide, and liraglutide have completely reshaped the global diabetes and obesity landscape
Having strategies in place for common side effects means fewer disruptions, fewer wasted doses, and better overall results per dollar spent
Zhao T, Chen H, Cheng C, et al
Despite extensive preventive efforts, over one billion people worldwide were affected by obesity in 2022 [1]
Brechner at our Lincoln Park clinic or via telehealth (available throughout Illinois)